ABB

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

Abbott Announces Positive Nine-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Absorbable Stent Continues to Show Promise as Future-GenerationTechnology BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced positive results from ABSORB, the world's firstclinical trial evaluating the safety and performance of a fullybioabsorbable drug eluting stent platform for the treatment ofcoronary artery disease. Nine-month results from the first 30pati...

Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials

SPIRIT FIRST Demonstrates Continued Safety for XIENCE V with NoLate Stent Thrombosis or Additional Major Adverse Cardiac EventsOut to Three Years BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ --Three-year data from the SPIRIT FIRST trial demonstrated noadditional Major Adverse Cardiac Events (MACE), and no late stentthrombosis in patients treated with either Abbott's XIENCE(TM) V...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

HUMIRA Data Showed 57 Percent Reduction in Risk of Hospitalizationfrom Crohn's Disease vs. Placebo at One Year ABBOTT PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced results from a post-hoc analysis of a pivotal studypresented at the Digestive Disease Week annual meeting inWashington, D.C. showing patients with moderate to severely activeCrohn's disease treated wi...

Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study

Most Patients Achieved at Least 75 Percent Improvement in PsoriasisSigns and Symptoms at Week 12; in Four of Five Dosing Groups, MoreThan Half Achieved 90 Percent Improvement ABBOTT PARK, Ill., May 04, 2007 /PRNewswire-FirstCall/ -- NewPhase II study results show Abbott's investigational treatment,ABT-874, reduced psoriasis symptoms significantly in the majorityof patients treated. At 12...

Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer

Scientists to Present Data on Innovative Oncology Compounds at theAmerican Association for Cancer Research Annual Meeting ABBOTT PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- Fordecades, scientists have looked for new therapies that targetcancer. Researchers now know that cancer cells have several uniquecharacteristics -- they require new blood vessels to deliver oxygenand nutrient...

Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke

EXACT and CAPTURE 2 Findings Suggest Improved Outcomes in CarotidArtery Stenting ABBOTT PARK, Ill., March 26, 2007 /PRNewswire-FirstCall/ --Positive 30-day results from two Abbott studies confirm thatcarotid stenting can be performed with positive results byphysicians with a variety of background experience in real-world(non-clinical trial) settings in patients who are not favorablecandi...

Abbott Announces Positive Six-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

Abbott's Bioabsorbable Stent Technology Holds Promise asFuture-Generation Treatment Option for Physicians Treating Patientswith Coronary Artery Disease ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ --Abbott today announced positive results from ABSORB, the world'sfirst clinical trial evaluating the overall safety and performanceof a fully bioabsorbable drug- eluting stent platf...

Abbott's Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial

- XIENCE V Demonstrates Superiority in Primary Endpoint ofIn-Segment Late Loss, Non-Inferiority in Major Secondary Endpointof Target Vessel Failure and Superiority in Major Adverse CardiacEvents (MACE) in the SPIRIT III U.S. Trial - ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Datapresented today from Abbott's SPIRIT III U.S. pivotal clinicaltrial at the of Cardiology's 56t...

Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiology's 56th Annual Scientific Session

Highlights Include First U.S. Clinical Data on XIENCE V EverolimusEluting Coronary Stent System and Six-Month Patient Follow-UpResults from the ABSORB Bioabsorbable Stent Clinical Study ABBOTT PARK, Ill., March 19, 2007 /PRNewswire-FirstCall/ --Abbott will present data from several studies across its broadvascular portfolio and pipeline during a number of late-breakingclinical...